Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Wijkman, MO, Claggett, B, Diaz, R, Gerstein, HC, Køber, L, Lewis, E, Maggioni, AP, Wolsk, E, Aguilar, D, Bentley-Lewis, R, McMurray, JJ, Probstfield, J, Riddle, M, Tardif, J-C, Solomon, SD & Pfeffer, MA 2020, 'Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial', Cardiovascular Diabetology, bind 19, nr. 1, s. 175. https://doi.org/10.1186/s12933-020-01150-0

APA

Wijkman, M. O., Claggett, B., Diaz, R., Gerstein, H. C., Køber, L., Lewis, E., Maggioni, A. P., Wolsk, E., Aguilar, D., Bentley-Lewis, R., McMurray, J. J., Probstfield, J., Riddle, M., Tardif, J-C., Solomon, S. D., & Pfeffer, M. A. (2020). Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology, 19(1), 175. https://doi.org/10.1186/s12933-020-01150-0

CBE

Wijkman MO, Claggett B, Diaz R, Gerstein HC, Køber L, Lewis E, Maggioni AP, Wolsk E, Aguilar D, Bentley-Lewis R, McMurray JJ, Probstfield J, Riddle M, Tardif J-C, Solomon SD, Pfeffer MA. 2020. Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. Cardiovascular Diabetology. 19(1):175. https://doi.org/10.1186/s12933-020-01150-0

MLA

Vancouver

Author

Wijkman, Magnus O ; Claggett, Brian ; Diaz, Rafael ; Gerstein, Hertzel C ; Køber, Lars ; Lewis, Eldrin ; Maggioni, Aldo P ; Wolsk, Emil ; Aguilar, David ; Bentley-Lewis, Rhonda ; McMurray, John J ; Probstfield, Jeffrey ; Riddle, Matthew ; Tardif, Jean-Claude ; Solomon, Scott D ; Pfeffer, Marc A. / Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial. I: Cardiovascular Diabetology. 2020 ; Bind 19, Nr. 1. s. 175.

Bibtex

@article{705dcb0fdd23459f8dee2b93be52f93f,
title = "Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial",
abstract = "BACKGROUND: The relationship between blood pressure and mortality in type 2 diabetes (T2DM) is controversial, with concern for increased risk associated with excessively lowered blood pressure.METHODS: We evaluated whether prior cardiovascular disease (CVD) altered the relationship between baseline blood pressure and all-cause mortality in 5852 patients with T2DM and a recent acute coronary syndrome (ACS) who participated in the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial. Risk of death was assessed in Cox models adjusted for age, sex, race, heart rate, BMI, smoking, diabetes duration, insulin use, HbA1c, eGFR, brain natriuretic peptide (BNP), urine albumin/creatinine ratio, treatment allocation and prior coronary revascularization.RESULTS: Although overall there was no significant association between systolic blood pressure (SBP) and mortality (hazard ratio per 10 mmHg lower SBP 1.05 (95% CI 0.99-1.12) P = 0.10), lower SBP was significantly associated with higher risk of death (hazard ratio per 10 mmHg lower SBP 1.13 (95% CI 1.04-1.22) P = 0.002) in 2325 patients with additional CVD (index ACS+ at least one of the following prior to randomization: myocardial infarction other than the index ACS, stroke or heart failure). In 3527 patients with only the index ACS no significant association was observed (hazard ratio per 10 mmHg lower SBP 0.95 (0.86-1.04) P = 0.26; P for interaction 0.005).CONCLUSIONS: The association between blood pressure and mortality was modified by additional CVD history in patients with type 2 diabetes and a recent coronary event. When blood pressures measured after an acute coronary event are used to assess the risk of death in patients with type 2 diabetes, the cardiovascular history needs to be taken into consideration. Trial registration ClinicalTrials.gov number NCT01147250, first posted June 22, 2010.",
author = "Wijkman, {Magnus O} and Brian Claggett and Rafael Diaz and Gerstein, {Hertzel C} and Lars K{\o}ber and Eldrin Lewis and Maggioni, {Aldo P} and Emil Wolsk and David Aguilar and Rhonda Bentley-Lewis and McMurray, {John J} and Jeffrey Probstfield and Matthew Riddle and Jean-Claude Tardif and Solomon, {Scott D} and Pfeffer, {Marc A}",
year = "2020",
month = oct,
day = "12",
doi = "10.1186/s12933-020-01150-0",
language = "English",
volume = "19",
pages = "175",
journal = "Cardiovascular Diabetology",
issn = "1475-2840",
publisher = "BioMed Central Ltd",
number = "1",

}

RIS

TY - JOUR

T1 - Blood pressure and mortality in patients with type 2 diabetes and a recent coronary event in the ELIXA trial

AU - Wijkman, Magnus O

AU - Claggett, Brian

AU - Diaz, Rafael

AU - Gerstein, Hertzel C

AU - Køber, Lars

AU - Lewis, Eldrin

AU - Maggioni, Aldo P

AU - Wolsk, Emil

AU - Aguilar, David

AU - Bentley-Lewis, Rhonda

AU - McMurray, John J

AU - Probstfield, Jeffrey

AU - Riddle, Matthew

AU - Tardif, Jean-Claude

AU - Solomon, Scott D

AU - Pfeffer, Marc A

PY - 2020/10/12

Y1 - 2020/10/12

N2 - BACKGROUND: The relationship between blood pressure and mortality in type 2 diabetes (T2DM) is controversial, with concern for increased risk associated with excessively lowered blood pressure.METHODS: We evaluated whether prior cardiovascular disease (CVD) altered the relationship between baseline blood pressure and all-cause mortality in 5852 patients with T2DM and a recent acute coronary syndrome (ACS) who participated in the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial. Risk of death was assessed in Cox models adjusted for age, sex, race, heart rate, BMI, smoking, diabetes duration, insulin use, HbA1c, eGFR, brain natriuretic peptide (BNP), urine albumin/creatinine ratio, treatment allocation and prior coronary revascularization.RESULTS: Although overall there was no significant association between systolic blood pressure (SBP) and mortality (hazard ratio per 10 mmHg lower SBP 1.05 (95% CI 0.99-1.12) P = 0.10), lower SBP was significantly associated with higher risk of death (hazard ratio per 10 mmHg lower SBP 1.13 (95% CI 1.04-1.22) P = 0.002) in 2325 patients with additional CVD (index ACS+ at least one of the following prior to randomization: myocardial infarction other than the index ACS, stroke or heart failure). In 3527 patients with only the index ACS no significant association was observed (hazard ratio per 10 mmHg lower SBP 0.95 (0.86-1.04) P = 0.26; P for interaction 0.005).CONCLUSIONS: The association between blood pressure and mortality was modified by additional CVD history in patients with type 2 diabetes and a recent coronary event. When blood pressures measured after an acute coronary event are used to assess the risk of death in patients with type 2 diabetes, the cardiovascular history needs to be taken into consideration. Trial registration ClinicalTrials.gov number NCT01147250, first posted June 22, 2010.

AB - BACKGROUND: The relationship between blood pressure and mortality in type 2 diabetes (T2DM) is controversial, with concern for increased risk associated with excessively lowered blood pressure.METHODS: We evaluated whether prior cardiovascular disease (CVD) altered the relationship between baseline blood pressure and all-cause mortality in 5852 patients with T2DM and a recent acute coronary syndrome (ACS) who participated in the ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) trial. Risk of death was assessed in Cox models adjusted for age, sex, race, heart rate, BMI, smoking, diabetes duration, insulin use, HbA1c, eGFR, brain natriuretic peptide (BNP), urine albumin/creatinine ratio, treatment allocation and prior coronary revascularization.RESULTS: Although overall there was no significant association between systolic blood pressure (SBP) and mortality (hazard ratio per 10 mmHg lower SBP 1.05 (95% CI 0.99-1.12) P = 0.10), lower SBP was significantly associated with higher risk of death (hazard ratio per 10 mmHg lower SBP 1.13 (95% CI 1.04-1.22) P = 0.002) in 2325 patients with additional CVD (index ACS+ at least one of the following prior to randomization: myocardial infarction other than the index ACS, stroke or heart failure). In 3527 patients with only the index ACS no significant association was observed (hazard ratio per 10 mmHg lower SBP 0.95 (0.86-1.04) P = 0.26; P for interaction 0.005).CONCLUSIONS: The association between blood pressure and mortality was modified by additional CVD history in patients with type 2 diabetes and a recent coronary event. When blood pressures measured after an acute coronary event are used to assess the risk of death in patients with type 2 diabetes, the cardiovascular history needs to be taken into consideration. Trial registration ClinicalTrials.gov number NCT01147250, first posted June 22, 2010.

U2 - 10.1186/s12933-020-01150-0

DO - 10.1186/s12933-020-01150-0

M3 - Journal article

C2 - 33046070

VL - 19

SP - 175

JO - Cardiovascular Diabetology

JF - Cardiovascular Diabetology

SN - 1475-2840

IS - 1

ER -

ID: 62055719